Manitoba Tumour Bank, Canada

Certification Status: Approved

Registration Status: Completed

Objective: THE MTB was established in 1993 as a Breast Tumour Bank, and in 2006 expanded to include collections in Chronic Lymphocytic Leukemia and other leukemias, lung cancer and Head & Neck Cancers. Recently the MTB has begun collections in ovarian cancer and prostate cancer. The MTB aims to provide a high quality research resource to support the mandate of the Research Institute in Oncology and Hematology (a joint institute of the Cancercare Manitoba and the University of Manitoba to improve the outcomes of patients and populations at risk of cancer and blood disorders in Manitoba, Canada and the World.

Registered Biobank Name	Manitoba Tumour Bank (MTB)
Biobank Leader	Leigh Murphy
Country	Canada
Email for biobank inquiries	leigh.murphy@umanitoba.ca
Principal Investigator	Leigh Murphy
Website	http://www.umanitoba.ca/institutes/manitoba_institute_cell_biology/MBTB/Index4.htm
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).